Oppenheimer Asset Management Inc. Sells 13,651 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Oppenheimer Asset Management Inc. decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,905 shares of the medical research company's stock after selling 13,651 shares during the quarter. Oppenheimer Asset Management Inc. owned approximately 0.06% of Charles River Laboratories International worth $6,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Versant Capital Management Inc grew its stake in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. increased its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after buying an additional 173 shares during the period. ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Charles River Laboratories International during the third quarter worth $59,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CRL has been the topic of several recent research reports. TD Cowen raised their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research note on Monday. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 18th. Finally, Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $198.36.

Charles River Laboratories International Trading Up 1.4 %

Shares of Charles River Laboratories International stock traded up $2.31 during trading hours on Tuesday, hitting $165.81. The company's stock had a trading volume of 628,773 shares, compared to its average volume of 690,085. The company has a market capitalization of $8.48 billion, a PE ratio of 1,105.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a 50 day moving average of $170.50 and a 200 day moving average of $186.58. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the prior year, the business earned $2.46 EPS. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).